Stifel raised the firm’s price target on Alignment Healthcare (ALHC) to $16 from $14 and keeps a Buy rating on the shares after the company reported “strong” results and reiterated its prior 2024 and 2025 guidance. Alignment “continued to separate themselves from the field in 2024/2025” and continued to take share while competitors have struggled, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare Promotes Maroney Amidst Strong Membership Growth
- Alignment Healthcare health plan membership on Jan 1 was 209,900
- Stephens lays out 21 Best Ideas for 2025
- Unusually active option classes on open December 4th
- Alignment Healthcare upgraded to Overweight from Equal Weight at Stephens